Printer Friendly

ICI AND BARR LABORATORIES SETTLE SUIT CONCERNING LEADING BREAST CANCER MEDICATION

 March 8 /PRNewswire/ -- Imperial Chemical Industries PLC (NYSE: ICI) and Barr Laboratories Inc. (Barr) have reached an out-of-court settlement of a patent dispute involving ICI's United States patent on tamoxifen citrate.
 To resolve the dispute, the parties have agreed to dismiss all claims raised in the action and have asked the U.S. Court of Appeals for the Federal Circuit to vacate the judgment of the U.S. District Court for the Southern District of New York finding the patent unenforceable. ICI was in the process of appealing the District Court decision when the settlement was reached. In agreeing to the settlement, Barr has acknowledged that there were genuine issues presented on appeal and risks of litigation. Barr and ICI also agreed that there was a substantial possibility that ICI's United States patent on tamoxifen would have been held valid and enforceable.
 Under the terms of the settlement, which are viewed as commercially satisfactory to both ICI and Barr, a total cash payment of $21 million will be made to Barr, Barr will enter into a non-exclusive distributorship agreement with ZENECA Inc., a United States affiliate of ICI, and Barr will begin selling generic tamoxifen citrate as of Nov. 1, 1993. The terms are contingent on the vacating of the judgment and the dismissal of the case. The Barr tamoxifen citrate product will be manufactured at the same facility as the innovator's product.
 ICI is one of the largest chemical companies in the world. ICI's pharmaceutical business unit is now held through ZENECA Limited and its U.S. pharmaceutical business is part of ZENECA Inc., based in Wilmington, Del. Major research targets include breast and prostate cancer, heart disease, CNS disorders and pulmonary diseases.
 Barr, headquartered in Pomona, N.Y., is one of America's largest independent generic drug companies. Barr manufactures and distributes generic prescription drug products in various dosage forms and strengths from its state-of-the-art manufacturing and distributing facilities in Northvale, N.J. and Pomona. Marketing generic tamoxifen citrate will complement Barr's extensive oncology product line which includes methotrexate and leucovorin calcium.
 -0- 3/8/93
 /CONTACT: Ed Seage of Imperial Chemical Industries PLC, 212-644-9292, or Steven Lampert of ZENECA Inc., 302-886-7862, or Harold Cohen of Barr Laboratories, 914-362-2823/
 (ICI)


CO: Imperial Chemical Industries PLC; Barr Laboratories Inc.;
 ZENECA Inc. ST: Delaware, New York IN: CHM SU:


TS -- NY028 -- 3865 03/08/93 09:34 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 8, 1993
Words:397
Previous Article:SOUTHWEST AIRLINES REPORTS FEBRUARY TRAFFIC UP 15.3 PERCENT
Next Article:UNIVERSAL SEISMIC ASSOCIATES, INC. COMMENCES 1,600,000 SHARE COMMON STOCK OFFERING
Topics:


Related Articles
ICI WILL APPEAL VIGOROUSLY U.S. COURT DECISION ON PATENT FOR LEADING BREAST CANCER MEDICATION
BARR WINS PATENT SUIT ON NOLVADEX
BARR-ICI SETTLEMENT IS FINALIZED
LEADING BREAST CANCER MEDICATION CLEARED FOR USE IN MEN NEW INDICATION OFFERS VALUABLE ALTERNATIVE TO SURGERY
BARR LABORATORIES LAUNCHES MEGESTROL ACETATE CANCER TREATMENT; FIRST NEW PRODUCT FROM 1994 PORTFOLIO OF DEVELOPMENT CANDIDATES
BARR LABORATORIES CHALLENGING PROZAC PATENTS
Barr Launches 20 mg Megestrol Acetate Tablet; Rounds-Out Megestrol Solid Oral Dosage Line
Barr Wins Another Pre-Trial Victory in DuPont Anti-Trust Suit.
Barr Seeks to Intervene in Zeneca Inc.'s EVISTA Suit.
Drug Companies Hit With Antitrust Lawsuit For Monopolizing Breast Cancer Drug Market.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters